share_log

康泰生物(300601.SZ):部分募投项目结项并将节余募集资金永久补充流动资金

Shenzhen Kangtai Biological Products (300601.SZ): Some fundraising projects have been completed, and the surplus funds will be permanently used to supplement working capital.

Gelonghui Finance ·  Dec 31, 2024 20:44

On December 31, Gelonghui reported that Shenzhen Kangtai Biological Products (300601.SZ) announced that it will hold the 25th meeting of the 7th Board of Directors and the 19th meeting of the 7th Supervisory Board on December 31, 2024. The meetings reviewed and approved the proposal to conclude the fundraising projects for the issuance of convertible corporate bonds to unspecified objects and to permanently supplement working capital with the surplus raised funds. Given that the company's fundraising projects for the issuance of convertible corporate bonds (hereinafter referred to as "fundraising projects"), including the "Baiwangxin Emergency Engineering & Construction Project" and the "Adenovirus Vector COVID-19 Vaccine Workshop Project," have been completed, in order to improve the efficiency of fund utilization and in conjunction with the company's actual operation situation, the company intends to conclude the above fundraising projects and permanently supplement working capital with the surplus fundraising amount of 133.0977 million yuan (including interest income, actual amount subject to the balance of the special account on the date of fund transfer), while authorizing relevant personnel from the company's finance department to handle the cancellation of this special account for the raised funds.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment